HHS's new peptide policy: what changed for BPC-157, TB-500 and 4 more

• HHS will not pursue licensed pharmacies, federal facilities or physicians that compound BPC-157, TB-500, Epitalon, KPV, MOTS-c or Semax for a patient with a prescription.
• Each compounded product may contain one listed peptide only, so a pharmacy cannot compound a BPC-157 + TB-500 blend under this policy.
• The bulk peptide must come from an FDA-registered manufacturer with a lot-specific certificate of analysis that meets a long testing table, endotoxins and residual solvents included.
• Routes are set per peptide: Semax is intranasal only, KPV topical or oral, TB-500, Epitalon and MOTS-c injectable only, BPC-157 injectable, oral or topical.
• It is an interim, non-binding policy, not an FDA approval; the FDA still decides each peptide through rulemaking, and comments are open for two weeks from 30 October 2026.

For three years, six of the most talked-about peptides sat in regulatory limbo. FDA staff said no, an FDA advisory panel said yes, and nothing moved. Then, on 28 October 2026, the Secretary of Health and Human Services skipped the queue. A new enforcement discretion policy tells licensed pharmacies and physicians that HHS will not come after them for compounding BPC-157, TB-500, Epitalon, KPV, MOTS-c or Semax for a patient, as long as they follow ten conditions (HHS).

The notice of availability ran in the Federal Register on 30 October 2026 under docket HHS-OASH-2026-0496, with written comments open for two weeks after publication (Federal Register). It is a short notice pointing to a sixteen-page policy, and the policy is where the interesting part lives.

Enforcement discretion is a regulator's way of saying that the law reads one way but the agency is choosing not to enforce it here, for now. It changes nothing in the statute. It simply moves these six peptides from a door marked closed to a door with a doorman and a very long checklist.

The policy does not cover "BPC-157" in any shape a pharmacy fancies. Appendix B pins down each peptide's identity (salt form, amino acid sequence, molecular formula and weight) and the routes HHS accepts for it (HHS).

Two details stand out. Semax, which many people know as an injectable research peptide, is covered only as a nasal product, because that is where the human record HHS cites comes from. And any pharmacy that compounds an oral peptide must keep documentation showing that the specific formulation reaches adequate oral bioavailability in humans, a bar most oral peptide products have never been asked to clear.

If you want to see what the identity data in that appendix looks like on real material, the Journal has walked through the structure and molecular weight of TB-500, MOTS-c, Epitalon and KPV.

HHS only steps back when every one of these is true (HHS):

1. The peptide is one of the six in Appendix A.
2. It matches the identity and route limits in Appendix B.
3. The bulk material comes from an FDA-registered facility and has a valid certificate of analysis meeting FDA's testing criteria.
4. The original manufacturer, not just a repacker or distributor, is FDA-registered, follows current good manufacturing practice and is named on the certificate with its address.
5. The compounder reports the products it makes, serious safety problems and quality problems to the FDA's MedWatch program and to the states involved.
6. The label says: "This is a compounded drug product. Not for resale."
7. Each product contains a single active ingredient from the list.
8. Oral products come with documentation of adequate oral bioavailability in humans.
9. The only delivery device packed with the product is one the FDA has cleared through 510(k).
10. Everything else in the FD&C Act still applies, including sanitary conditions and a patient-specific prescription.

Rule seven is the quiet blockbuster. The popular combinations, such as a BPC-157 + TB-500 vial, fall outside the policy entirely. HHS's reasoning is surveillance: if something goes wrong, a single-ingredient product makes it far easier to tell which substance was involved.

Read HHS's justifications and one phrase keeps coming back: lot-specific certificates. For BPC-157, HHS says the record now includes a lot-specific certificate from an FDA-registered facility reporting the identity, impurity, endotoxin, microbial and residual solvent results that FDA's drug center had found missing. Similar language appears for TB-500, Epitalon, Semax, KPV and MOTS-c (HHS).

Appendix B then sets out what such a certificate has to contain, and it is a serious document: identity by at least two independent analytical methods, an HPLC assay against a reference standard, net peptide content, peptide-related impurities, residual solvents by gas chromatography, elemental impurities by ICP-MS, residual TFA, counter-ion and water content, bioburden and bacterial endotoxins. Each test must name its method and validation report, and the certificate must carry a batch number, synthesis and release dates, an expiry or retest date and the manufacturer's FDA facility number.

In other words, the government's whole case rests on the same question every careful buyer already asks: does the paperwork match the lot? The Journal's guides to what to check on a BPC-157 lab report and to HPLC purity versus net peptide content cover the fields HHS now sets as the price of admission.

All six peptides sat in FDA's Category 2, the list of bulk substances that may raise significant safety concerns, from September 2023 until 22 April 2026. For each one, FDA's Center for Drug Evaluation and Research (CDER) recommended against adding it to the 503A bulks list, and the Pharmacy Compounding Advisory Committee voted in favour (HHS). At the July 2026 meeting the panel backed BPC-157 by 8 votes to 6 (STAT).

HHS gives the same three-part reason for nearly every peptide. First, the characterization record has changed, thanks to those certificates from FDA-registered manufacturers. Second, historical use is now documented and quantified, where CDER had found it unclear. Third, HHS describes the concerns CDER raised as inferred or mechanistic rather than observed, and points to the policy's own safeguards: lot-level testing, single-ingredient products and MedWatch reporting.

HHS also says plainly what it hopes to achieve: to steer patients toward a more controlled channel and to advance what it calls patient choice and freedom. It is a striking position for a health department to put in writing, and it is why this policy reads less like a technical memo and more like a statement of direction.

• It is not an FDA approval. Compounded drugs are not FDA-approved, and HHS says so in the notice.
• It is not a final rule. The FDA still has to decide, through rulemaking, whether each peptide joins the 503A bulks list. The policy says future rulemaking may propose adding some or all of them.
• It is not binding. HHS states that the policy creates no rights and that it may revisit it, in whole or in part, if a safety signal or quality problem appears.
• It only covers compounding. It is about pharmacies and physicians making a product for a named patient with a prescription. It says nothing new about research-grade material sold for laboratory use.

For the longer story of why these peptides never had an approval route in the first place, see why most research peptides are not FDA-approved.

Comments on the policy can be filed at regulations.gov under docket HHS-OASH-2026-0496 for two weeks after the 30 October publication (Federal Register). After that, the real decision moves back to the FDA, which must publish proposed rules for the bulks list and open a fresh round of public comment before anything becomes permanent.

Expect three things in the meantime: compounding pharmacies racing to source material that meets the Appendix B testing table, a scramble among bulk manufacturers to prove FDA registration, and a lot more attention on certificates of analysis from everyone in the peptide world. The door is open a crack. Who gets through it will be decided, lot by lot, on paper. For laboratory research, all six are in the NuuVive catalogue, each with its lab report.

1. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy, Appendix A and Appendix B). U.S. Department of Health and Human Services
2. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 2026-22192). Federal Register
3. FDA peptide compounding panel backs epitalon, rejects emideltide. STAT